Novel marker technology in cell therapy and cancer
Xintela develops novel therapies in regenerative medicine and cancer based on its patented integrin marker technology platform. In regenerative medicine, Xintela’s current focus is to develop an allogeneic mesenchymal stem cell therapy for treatment of the degenerative joint disease osteoarthritis in horses and human. The cancer project aims to develop antibody-drug conjugates (ADCs) for first-in-class cancer therapy, with prime focus on the aggressive brain tumor glioblastoma.
